Screening for prostate cancer with first-line MRI less cost-effective than first-line PSA testing

A cost-effectiveness analysis found that screening for prostate cancer using biparametric magnetic resonance imaging (bpMRI) as a first-line approach is less cost-effective than first-line prostate-specific antigen (PSA) testing with second-line multiparametric MRI (mpMRI).